- VLA2001, an inactivated COVID-19 vaccine candidate with CpG 1018 adjuvant, was highly immunogenic and generally safe and well tolerated
-- 100% seroconversion rate for S-protein binding IgG antibodies in the high dose group
-- Neutralizing antibody titers at or above levels seen in convalescent sera
-- Majority of adverse events were mild to moderate
- Valneva plans to initiate a Phase 3 immunogenicity study in April 2021, subject to regulatory approval
https://finance.yahoo.com/news/positive-phase-1-2-results-100000668.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.